Krista Davis Sells 1,730 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 1,730 shares of the business’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $77.99, for a total value of $134,922.70. Following the transaction, the senior vice president owned 49,263 shares of the company’s stock, valued at approximately $3,842,021.37. The trade was a 3.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Krista Davis also recently made the following trade(s):

• On Thursday, February 19th, Krista Davis sold 2,084 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $77.53, for a total value of $161,572.52.
• On Thursday, December 18th, Krista Davis sold 1,622 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $82.40, for a total value of $133,652.80.

ANI Pharmaceuticals Stock Up 2.1%

ANIP stock opened at $76.70 on Wednesday. The company’s 50 day moving average is $80.60 and its 200 day moving average is $86.60. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of 47.06 and a beta of 0.50. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20. ANI Pharmaceuticals, Inc. has a 1-year low of $54.10 and a 1-year high of $99.50.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $32,992,000. Balyasny Asset Management L.P. boosted its holdings in shares of ANI Pharmaceuticals by 2,785.7% during the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after buying an additional 276,233 shares in the last quarter. Divisadero Street Capital Management LP bought a new stake in shares of ANI Pharmaceuticals during the 3rd quarter valued at $21,454,000. Rubric Capital Management LP lifted its position in ANI Pharmaceuticals by 354.7% during the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after acquiring an additional 200,998 shares during the period. Finally, UBS Group AG lifted its position in ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after acquiring an additional 185,172 shares during the period. 76.05% of the stock is currently owned by institutional investors.

Key Stories Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Management will present at three major investor conferences in early March (Raymond James, Leerink Partners, Barclays); live and archived webcasts available on the company site for 90 days — helps visibility and investor access to management’s growth story. GlobeNewswire Release
• Positive Sentiment: Analyst coverage remains constructive: recent buy/overweight ratings and several price targets well above the current price (median/consensus targets indicate upside), supporting investor confidence. MarketBeat Analyst Notes
• Neutral Sentiment: Street preview pieces highlight expected strength in Cortrophin Gel and rare-disease momentum ahead of Q4 results — this implies potential upside but also flags generic pressure risks; outcome depends on reported numbers. Zacks Preview
• Neutral Sentiment: Recorded short-interest data in the feed shows zero shares / anomalous NaN change and a 0.0 days-to-cover metric — appears to be a data glitch and is unlikely to be an actionable signal by itself.
• Neutral Sentiment: Institutional/hedge-fund activity is mixed: some large reallocations reported (both adds and sizable removals across different funds in the latest quarter), so ownership trends are shifting but not uniformly bullish or bearish. Quiver Quant Summary
• Negative Sentiment: Several insiders (including SVP Krista Davis and Head of Rare Disease Christopher Mutz) disclosed market sales of ANIP shares in recent sessions; repeated insider selling can be perceived as a modest negative signal for near-term sentiment. InsiderTrades Filing

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ANIP shares. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Barclays began coverage on ANI Pharmaceuticals in a report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price objective for the company. Finally, Guggenheim raised their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. Six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $103.43.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.